A small randomized crossover trial indicates that treatment with empagliflozin in people with type 2 diabetes and heart failure already using a loop diuretic results in increased urine output without sodium loss.
A meta-analysis of the DAPA-HF and EMPEROR-Reduced trials supports use of SGLT2 inhibitors in people with heart failure with or without diabetes, and suggests a positive effect on mortality endpoints.
The EMPEROR-Reduced investigators have revealed that empagliflozin provides significant protection against cardiovascular death and heart failure in patients with heart failure and reduced ejection fraction, with or without diabetes.
The primary findings of the DAPA-CKD trial show that dapagliflozin significantly slows decline in kidney function in patients with chronic kidney disease irrespective of whether they have type 2 diabetes.
Among people with obesity and type 2 diabetes, substantial weight loss is associated with similar metabolic benefits irrespective of whether it is achieved through gastric bypass surgery or diet, suggests research published in The New England Journal of Medicine.
Both type 1 and type 2 diabetes are independently associated with an increased risk for death among hospitalized patients with COVID-19, and a number of factors including poor glycemic control and BMI may predict mortality risk, suggest findings from two studies published in The Lancet Diabetes & Endocrinology.
Researchers studying the MESA cohort have proposed BMI cutoffs at which people from ethnic minorities should be screened for type 2 diabetes, all of which are lower than their proposed cutoff for White people.
Severe hypoglycemia in people with type 2 diabetes is associated with later mortality from a wide range of causes, including those for which there is no obvious underlying mechanism, say researchers.
A large study of data from people with type 2 diabetes in general practice reveals that non-cardiovascular comorbidities such as osteoarthritis and depression are common, and significantly more so than in people without diabetes.
Focusing efforts on convincing people to return after the first session of the US National Diabetes Prevention Program lifestyle change program, and after the transition to less frequent sessions, may help to optimize program retention, say researchers.
The increased risk for prediabetes among ethnic minorities compared with White people is less pronounced in neighborhoods with high walkability, shows a Canadian study.
A novel insulin that can be given as a once-weekly injection has achieved promising results in a randomized phase 2 trial involving people with type 2 diabetes.
Icosapent ethyl reduces the risk for first and total cardiovascular events in statin-treated patients with diabetes, suggests a subgroup analysis of the REDUCE-IT trial.
Doctors are faster to initiate pharmacologic type 2 diabetes treatment in people from ethnic minorities than in White people but are then slower to intensify their treatment when needed, show data from the UK.
A study shows marked variations in cardiovascular risk burden according to age, sex, and ethnicity at the point of type 2 diabetes diagnosis, with implications for both diabetes prevention and cardiovascular risk management.
A major genetic analysis sheds light on the similarities and differences in type 2 diabetes pathogenesis between people of East Asian and European origin.
People who meet the criteria for prediabetes during the 3 years before a type 2 diabetes diagnosis have a higher burden of vascular disease than those who do not, research shows.
US primary care physician Neil Skolnik discusses the role of oral semaglutide in the care of people with type 2 diabetes and outlines key considerations for its use (12:26) [Listen now]
DiRECT trial dietitian Alison Barnes discusses the challenges and triumphs of using a very-low-calorie, total-meal-replacement diet to help people with type 2 diabetes achieve weight loss and maintenance (25:34).
06-24-2020 | ADA 2020 | Conference coverage | Article
Diagnosis and management of prediabetes: a consensus of GCC countries
Guidance based on outcomes of an advisory board of diabetes experts, for healthcare professionals addressing the diagnosis and treatment of prediabetes.
This interactive roadmap is intended for healthcare professionals practicing in Saudi Arabia, Kuwait, the United Arab Emirates, Qatar, Bahrain, and Oman.
Funding for this roadmap was provided by Merck Serono Middle East FZ-LLC
These slide sets summarize the results of clinical studies and randomized controlled trials investigating the use of flash glucose-sensing technology in patients with diabetes.
Funded by an educational grant from Abbott Diabetes Care
An updated collection of articles focusing on the mechanism of action and clinical use of sodium-glucose cotransporter-2 inhibitors in patients with diabetes.
The authors report on ameta-analysis of real-world observational studies on the impact of flash continuous glucose monitoring on glycemic control as measured by HbA1c.
A convenient single access point, providing diabetes professionals with links to a comprehensive set of clinical practice guidelines from a wide range of relevant organizations.
Practical information, guidance, and helpful resources for diabetes healthcare providers. Comprised of practical approaches, case studies, and more.
Themed collections
Compendia of selected, recently published, free full-text journal and book content from Springer Nature and other publishers on a particular topic within diabetes management, as recommended by our Editorial Board.
Educational programs building upon the most current research and professional practice recommendations, with the aim of enabling more efficient diagnosis, optimizing treatment, and improving patient outcomes.
